SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-21-162642
Filing Date
2021-05-17
Accepted
2021-05-17 06:06:20
Documents
55
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d143007d10q.htm 10-Q 663864
2 EX-31.1 d143007dex311.htm EX-31.1 6919
3 EX-31.2 d143007dex312.htm EX-31.2 6912
4 EX-32.1 d143007dex321.htm EX-32.1 3234
5 EX-32.2 d143007dex322.htm EX-32.2 3305
  Complete submission text file 0001193125-21-162642.txt   3036981

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT lsacu-20210331.xml EX-101.INS 496628
7 XBRL TAXONOMY EXTENSION SCHEMA lsacu-20210331.xsd EX-101.SCH 29226
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lsacu-20210331_cal.xml EX-101.CAL 25272
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lsacu-20210331_def.xml EX-101.DEF 121152
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE lsacu-20210331_lab.xml EX-101.LAB 267535
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lsacu-20210331_pre.xml EX-101.PRE 211401
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 21927278
SIC: 2834 Pharmaceutical Preparations